CytoSorbents: A Quick Rebound Indicates Belief in Progress and Potential (CTSO)

CytoSorbents Corporation (OTCBB: CTSO) is a publicly-traded, critical care focused therapeutic device company using blood purification to treat life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Each polymer bead contains millions of pores and channels that can be modified to remove substances as small as drugs, to substances as large as antibodies. 

At MarketPlayground.com, contributor VFC's StockHouse wrote an article analyzing the Company's recent share price drop and the possible reasons behind it.

He reminds investors,

"Cytosorbents is trucking along for a company its size and a technology that may be so good that doctors have to see it to believe it — and given that the European regulators were convinced to approve CytoSorb even before the final trial results were in, there’s a strong case to be made that the believers are out there."

He points out that in addition to moving forward with the commercial launch of CytoSorb, the Company is also making progress on other fronts, too: 

"The HemoDefend blood purification technology could help the company land a partner and lead to revenue while CytoSorb continues its roll-out, and the US Army has also jumped on board to support the company with the awarding of a grant late last year.

As those events unfold and pay dividends, 2012 could easily turn into another milestone year for CytoSorbents. The quick rebound from last week’s drop is a good indicator that there is a solid foundation of patient investors that believe the same and are willing to stick this one out."

 
Read more at MarketPlayground.com.